Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, MA, USA.
Soc Sci Med. 2023 Oct;335:116232. doi: 10.1016/j.socscimed.2023.116232. Epub 2023 Sep 9.
The dietary supplements industry disproportionately markets potentially harmful products promising weight loss, cleansing/detoxing, and boosted energy and immunity to women. The COVID-19 pandemic heightened consumer concerns around health and body weight, which may have increased women's risks of using supplements, particularly if they had a higher weight and experienced weight discrimination. This study aimed to estimate inequities in prevalence and change in use of weight-loss, cleanse/detox, immunity, and energy supplements in the first year of the pandemic and to assess the extent to which the relationship between weight and supplement use differs across discrimination experiences. We drew upon longitudinal data from cisgender women in the U.S. COVID-19 Pandemic Substudy of the Nurses' Health Study II and 3 and Growing Up Today Study cohorts, collected over 5 waves from April/May 2020 to April 2021 (N = 51,814). Modified Poisson generalized estimating equation models, adjusted for age, cohort, race/ethnicity, wave, and Census region, estimated the relative excess risk due to interaction (RERI) between weight status and weight discrimination on prevalence of supplement use. Weight status categories were derived from body mass index (BMI), and weight discrimination was assessed using the attributions item of the Everyday Discrimination Scale. Baseline prevalence of supplement use was 2.7% for weight-loss, 3.3% for cleanse/detox, 4.2% for energy, and 22.6% for immune. Respondents with BMIs of 25-29.9 kg/m and 30-34.9 kg/m who experienced weight discrimination had RERI values of 0.89 (95% CI 0.14, 1.65) and 1.00 (95% CI 0.25, 1.75) for weight-loss and 0.57 (95% CI 0.13, 1.02) and 0.60 (95% CI 0.19, 1.01) for energy supplements, respectively, indicating this group had excess risk of use compared to lower BMI respondents who experienced no weight discrimination. The findings demonstrate the disproportionate impact of weight discrimination on use of potentially harmful supplements among cisgender women with higher weights during the pandemic.
膳食补充剂行业不成比例地向女性推销潜在有害的产品,这些产品承诺能减肥、净化/排毒、提高能量和免疫力。COVID-19 大流行加剧了消费者对健康和体重的担忧,这可能增加了女性使用补充剂的风险,尤其是如果她们体重较高且经历了体重歧视。本研究旨在估计在大流行的第一年,减肥、净化/排毒、免疫和能量补充剂的使用在患病率和变化方面的不平等,并评估体重与补充剂使用之间的关系在多大程度上因歧视经历而有所不同。我们利用美国 COVID-19 大流行护士健康研究 II 和 3 以及今日成长研究队列的顺性别女性的纵向数据,从 2020 年 4 月/5 月至 2021 年 4 月共收集了 5 个波次(N=51814)。使用修正泊松广义估计方程模型,根据年龄、队列、种族/民族、波次和人口普查区域进行调整,估计体重状况和体重歧视与补充剂使用患病率之间的交互相对超额风险(RERI)。体重状况类别源自体重指数(BMI),体重歧视通过日常歧视量表的归因项目进行评估。补充剂使用的基线患病率分别为减肥 2.7%、净化/排毒 3.3%、能量 4.2%和免疫 22.6%。经历体重歧视的 BMI 为 25-29.9kg/m 和 30-34.9kg/m 的受访者,减肥和能量补充剂的 RERI 值分别为 0.89(95%CI 0.14,1.65)和 1.00(95%CI 0.25,1.75)和 0.57(95%CI 0.13,1.02)和 0.60(95%CI 0.19,1.01),表明与未经历体重歧视的 BMI 较低的受访者相比,这一群体使用这些补充剂的风险过高。研究结果表明,在大流行期间,体重歧视对体重较高的顺性别女性使用潜在有害补充剂的影响不成比例。